**GROUP INSURANCE – HEALTH CLAIMS** 



C. P. 3950 Lévis (Québec) G6V 8C6 desjardinslifeinsurance.com/planmember 1-844-410-6485

## PRIOR AUTHORIZATION REQUEST

DOPTOLET (AVATROMBOPAG) NPLATE (ROMIPLOSTIM)

**REVOLADE (ELTROMBOPAG)** TAVALISSE (FOSTAMATINIB)

			PLE	ASE REA	AD THE INSTRU	CTIONS ON	THE E	BACK OF	THIS FO	RM.		
Α	PATIENT IDENTIFICATION – To be completed by the member.											
	Patient's last and first name					Relatio	nship w	ith membe	r		Patient's o	late of birth
					🗌 🗌 Mei	mber	🗌 Spous	e 🗆	Dependent chi			
	Member's last and first name Contract No.							Certificate No.				
	No., street, apt. City F							Province	Postal code			
	Telephone Nos – Home:			Office:			Extensio			mail:		
	Since the response to this r									of the decision	:	
	Coordination of benefits: If the patient has coverage under a private insurance plan or is enrolled in a provincial drug insurance plan, please submit the request to this plan first. Then send us a copy of the decision notice and this form filled out by the physician, so we can analyze the request.											
		Does the patient have drug coverage under a private insurance plan?										
		$\Box$ Yes – Please provide a copy of the notice of approval or refusal. $\rightarrow$ $\Box$ Copy attached to this form.										
	PRIVATE PLAN	Specify: N	lame of the	insurer: _				_ Contract	No.:		Certificate N	0.:
		No										
	PROVINCIAL PLAN	Has a request for reimbursement been submitted under your provincial plan? ✓ Yes – Please provide a copy of the notice of approval or refusal. → Copy attached to this form. ✓ No – Please explain:										
		Is the pat	ient enrolleo	d in a pati	ent support progra	am? 🗌 Yes	s 🗌 No	)				
	PATIENT SUPPORT PROGRAM	<b>If so</b> – Pro	ogram name	:								
		Contact p	erson:					Telep	ohone No.	:		Extension:
	he information deemed necessary to manage my file. The non-exhaustive list of sources from which information may be collected includes healthcare professionals or facilities, and insurance companies; (b) communicate to the said persons or organizations only the personal information about me that is deemed necessary for the purposes of my file; (c) when necessary use the personal information it may have about me in existing files that are now closed. This authorization is also valid for the collection, use and communication of personal information concerning my dependents, insofar as applicable to the claim. A photocopy of this authorization is as valid as the original.											
>	Signature of member: Date:											
	Last name and first name o	Last name and first name of parent/legal guardian (if applicable):										
	Signature of patient or par	Signature of patient or parent/legal guardian (if applicable): Date:										
<b>B2</b>	CONSENT TO THE COMMUNICATION OF PERSONAL INFORMATION TO A THIRD PARTY											
	To help us process your claim more efficiently, do you authorize Desjardins Insurance to inform the patient support program and the attending physician or the attending physician's medical team of the reasons for the decision on your prior authorization request?											
	Yes No											
>	Signature of member:								Da	te:		
	Last name and first name of parent/legal guardian (if applicable):											
	Signature of patient or parent/legal guardian (if applicable): Date:											
C	ATTENDING PHYSICIAI	N SECTION	– To be com	pleted by	y the attending phy	ysician.						
	Physician's last and first name (PLEASE PRINT)					Licens	e No.		Specialty			
	No., street, suite City P						Province	Postal code				
	Telephone No.: Fax No.:											
>	Signature of physician:									Date:		
•	Drug name				Formulation	Strength	[	Dosage	Pa	tient's weight	Scheduled du	ration of treatment
	Where is the drug administ	tered?	Home	Phys	ician's office	Private clir	nic	Hospita	l – Inpatie	ent 🗌 Hos	pital – Outpatie	nt

Other (please specify):

## **C** ATTENDING PHYSICIAN SECTION – Continued

D

• Make sure to fill out all sections so we can process the request faster. If any information is missing, we will send the form back to the member.

• In order to consider any diagnosis not mentioned on this form, we need supporting documents (clinical practice guidelines, clinical studies, etc.) that justify the drug's use in the given context.

Diagnosis							
Severe aplastic anemia							
🗌 Immune thrombocytopenia							
$\Box$ Thrombocytopenia in patients with chronic hepatitis C							
Other therapeutic indication(s) – Please specify:							
INFORMATION RELATING TO IMMUNE THROMBOCYT	OPENIA						
Please indicate initial platelet count (prior to initiation of N	/IG therapy, if applicable): 10º/L						
Does the patient has bleeding or documented risk of bleed	ling? 🗌 Yes 🗌 No						
PRIOR MEDICATION OR TREATMENT Has the patient ever used medication or received treatment	nt for this medical condition? $\Box$ Yes $\Box$ No						
If not, please explain:							
If so, please list any medication already used or any treatm	nent already received for this medical condition:						
MEDICATION OR TREATMENT NAME	Ουτςομε	TREATMENT PERIOD					
Name:	Inefficiency Intolerance Contraindication	YYYY MM DD From:					
Dose:	Specify:	YYYY MM DD To:					
Name:	Intolerance Contraindication	YYYY MM DD From:					
Dose:	Specify:	YYYY MM DD To:					
Name:	Inefficiency Intolerance Contraindication	YYYY MM DD From:					
Dose:	Specify:	YYYY MM DD To:					
Name:	Inefficiency Intolerance Contraindication	From:					
Dose:	Specify:	YYYY MM DD To:					
PRESCRIPTION RENEWAL							
Please provide the platelet count following treatment:	10º/L						
For a diagnosis of severe aplastic anemia, please provide	one of the following: Platelet count increase:	10º/L					
	Hemoglobin increase:	g/L					
	Absolute neutrophils count increase:	%					
INSTRUCTIONS – HOW TO COMPLETE AND RETU		•					
1. Complete sections A and B.							
·	er is responsible for assuming any costs incurred to complete this form or t	o obtain additional information.					
	pproved, please use your payment card at the pharmacy or submit your or						

4.	Send form:	by fax:	Desjardins Insurance	by mail:	Desjardins Insurance
			Group Insurance, Health Claims,		Group Insurance, Health Claims
			418-838-2134 or 1-877-838-2134 (toll-free)		C. P. 3950, Lévis (Québec) G6V 8C6

Under its prior authorization program, Desjardins Insurance authorizes the reimbursement of certain drugs that meet criteria that are based, in particular, on clinical practice guidelines and recommendations issued by health technology assessment organizations. The drug will be eligible for reimbursement if it meets the insurer's criteria, if it's not administered in a hospital and if it's not eligible under a government program. If the information on your form is complete, your request will normally be processed within 5 business days.

When the request form is received, it will be assessed in the strictest confidence. In some situations, additional diagnostic or clinical information may be required.

If the treatment continues beyond the authorized period, you will be asked to submit a new request form and provide information that justifies the extension of treatment. If you have a payment card, your pharmacist will be advised that the authorization period is coming to an end. The insurance must be in force and the patient still covered on the date expenses are incurred. This prior authorization is subject to change if, at the time expenses are incurred, the contract has been modified.

When Desjardins Insurance declines a prior authorization request, it is because we need to uphold conditions set out in the contract. It does not mean we are questioning the physician's opinion. If you have any questions, please contact our Customer Contact Centre at the number indicated on page 1 of this form.